<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00983320</url>
  </required_header>
  <id_info>
    <org_study_id>D1443C00017</org_study_id>
    <nct_id>NCT00983320</nct_id>
  </id_info>
  <brief_title>Quetiapine (Seroquel XR) for the Treatment of Fibromyalgia: a Clinical and Mechanistic Pilot Study</brief_title>
  <official_title>Quetiapine (Seroquel XR) for the Treatment of Fibromyalgia: a Clinical and Mechanistic Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université de Sherbrooke</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Université de Montréal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Université de Sherbrooke</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blind, randomized, placebo-controlled trial measuring the impact of&#xD;
      quetiapine on clinical and experimental measures of pain in fibromyalgia and its biochemical&#xD;
      correlates.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind, randomized, placebo-controlled trial measuring the impact of&#xD;
      quetiapine on clinical and experimental measures of pain in fibromyalgia. The study also&#xD;
      seeks to measure the hormonal, immunological and neurochemical correlates of clinical changes&#xD;
      in time.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fibromyalgia impact questionnaire</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Thermal pain threshold</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Fibromyalgia</condition>
  <arm_group>
    <arm_group_label>medication</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>quetiapine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>quetiapine</intervention_name>
    <description>flexible dosage (50 to 300 mg)</description>
    <arm_group_label>medication</arm_group_label>
    <other_name>Seroquel XR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provision of written informed consent&#xD;
&#xD;
          -  A diagnosis of Fibromyalgia using the American College of Rheumatology criteria&#xD;
&#xD;
          -  Females aged between 18 to 65 years&#xD;
&#xD;
          -  Patients with an unsatisfactory response to their previous pharmacological treatment,&#xD;
             defined as a score ≥4 on the pain severity item of the Fibromyalgia Impact&#xD;
             Questionnaire&#xD;
&#xD;
          -  Female patients of childbearing potential must be using a reliable method of&#xD;
             contraception and have a negative urine human chorionic gonadotropin (HCG) test at&#xD;
             enrolment&#xD;
&#xD;
          -  Patients receiving pharmacological treatment for fibromyalgia&#xD;
&#xD;
          -  Able to understand and comply with the requirements of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Patients with DSM-IV Axis 1 disorder other than MDD and Chronic Pain Disorder within 6&#xD;
             months of enrolment&#xD;
&#xD;
          -  Elderly patients with dementia and behavioural disturbances&#xD;
&#xD;
          -  Patients who, in the investigator's opinion, pose a risk for suicide&#xD;
&#xD;
          -  Known intolerance or lack of response to quetiapine fumarate, as judged by the&#xD;
             investigator&#xD;
&#xD;
          -  Use of any of the following cytochrome P450 3A4 inhibitors in the 14 days preceding&#xD;
             enrolment including but not limited to: ketoconazole, itraconazole, fluconazole,&#xD;
             erythromycin, clarithromycin, troleandomycin, indinavir, nelfinavir, ritonavir,&#xD;
             fluvoxamine and saquinavir&#xD;
&#xD;
          -  Use of any of the following cytochrome P450 inducers in the 14 days preceding&#xD;
             enrollment including but not limited to: phenytoin, carbamazepine, barbiturates,&#xD;
             rifampin, St. John's Wort, and glucocorticoids&#xD;
&#xD;
          -  Patients already receiving an antipsychotic medication&#xD;
&#xD;
          -  Current substance abuse/dependence (last year), as defined by DSM-IV criteria.&#xD;
             Psychoactive substances include: alcohol, amphetamine, barbiturate, benzodiazepine,&#xD;
             cannabis, cocaine, hallucinogen, opiates and phencyclidine&#xD;
&#xD;
          -  Medical conditions that would affect absorption, distribution, metabolism, or&#xD;
             excretion of study treatment This could relate to patients with GI problems (short GI&#xD;
             transit), Crohn's disease or disease requiring treatment with restricted medications&#xD;
             as indicated in exclusion criteria items 5 and 6.&#xD;
&#xD;
          -  Unstable or inadequately treated medical illness (e.g. congestive heart failure,&#xD;
             angina pectoris, hypertension, hypotension) as judged by the investigator, based on&#xD;
             the results from the physical exam, ECG, haematology, chemistry and urine screenings&#xD;
&#xD;
          -  Participation in another drug trial within 4 weeks prior enrolment into this study&#xD;
&#xD;
          -  A patient with Diabetes Mellitus (DM) fulfilling one of the following criteria:&#xD;
&#xD;
               -  Unstable DM defined as enrolment glycosylated hemoglobin (HbA1c) &gt;8.5%.&#xD;
&#xD;
               -  Admitted to hospital for treatment of DM or DM related illness in past 12 weeks.&#xD;
&#xD;
               -  Not under physician care for DM&#xD;
&#xD;
               -  Physician responsible for patient's DM care has not indicated that patient's DM&#xD;
                  is controlled.&#xD;
&#xD;
               -  Physician responsible for patient's DM care has not approved patient's&#xD;
                  participation in the study&#xD;
&#xD;
               -  Has not been on the same dose of oral hypoglycaemic drug(s) and/or diet for the 4&#xD;
                  weeks prior to randomization. For thiazolidinediones (glitazones) this period&#xD;
                  should not be less than 8 Weeks.&#xD;
&#xD;
               -  Taking insulin whose daily dose on one occasion in the past 4 weeks has been more&#xD;
                  than 10% above or below their mean dose in the preceding 4 weeks Note: If a&#xD;
                  diabetic patient meets one of these criteria, the patient is to be excluded even&#xD;
                  if the treating physician believes that the patient is stable and can participate&#xD;
                  in the study.&#xD;
&#xD;
          -  An absolute neutrophil count (ANC) of less or equal to 1.5 x 109 per liter&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Serge Marchand, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université de Sherbrooke</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Hidalgo J, Rico-Villademoros F, Calandre EP. An open-label study of quetiapine in the treatment of fibromyalgia. Prog Neuropsychopharmacol Biol Psychiatry. 2007 Jan 30;31(1):71-7. Epub 2006 Aug 4.</citation>
    <PMID>16889882</PMID>
  </reference>
  <verification_date>October 2011</verification_date>
  <study_first_submitted>September 23, 2009</study_first_submitted>
  <study_first_submitted_qc>September 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2009</study_first_posted>
  <last_update_submitted>October 4, 2011</last_update_submitted>
  <last_update_submitted_qc>October 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Université de Sherbrooke</investigator_affiliation>
    <investigator_full_name>Serge Marchand</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Fibromyalgia</keyword>
  <keyword>pain</keyword>
  <keyword>quetiapine</keyword>
  <keyword>randomized placebo controlled trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Quetiapine Fumarate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

